期刊文献+

胃肠胰神经内分泌肿瘤诊治理念更新与焦点问题 被引量:3

Renewal of ideas and focus of gastroenteropancreatic neuroendocrine neoplasm
原文传递
导出
摘要 胃肠胰神经内分泌肿瘤(GEP-NENs)的发病率逐年增加,在这类肿瘤的诊治过程中,应充分重视多学科合作和建立区域诊治中心的重要性。改善生活质量、延长存活期和控制激素过量分泌的相关症状是神经内分泌肿瘤治疗的主要目标。这一领域仍有许多尚待解决的焦点问题,如准确的病理分级和分期、发现诊断和治疗的分子靶标、什么是适宜的治疗顺序和疗效评价手段、是否所有的神经内分泌瘤都需要治疗等,这些问题的解决有助于改善GEP-NENs的治疗效果。 The incidence of gastroenteropancreatic neuroendocrine neoplasm (GEP-NENs) is increasing. More emphasis should be paid to the muhidisciplinary cooperation and construction of regional center of excellence. The goals of treatment for GEP-NENs are improving quality of life, prolonging survival and control of symptom related to excessive hormone secretion. There are still lots of problems need to be solved in this field, such as accurate pathological grade and stage, molecular target for diagnosis and treatment, proper treatment sequence and evaluation criteria, and whether all neuroendocrine tumor need to be treated. The answers to these questions will improve the outcome of GEP-NENs.
作者 楼文晖
出处 《中国实用外科杂志》 CSCD 北大核心 2014年第6期476-478,共3页 Chinese Journal of Practical Surgery
关键词 胃肠胰神经内分泌肿瘤 多学科团队 区域诊治中心 gastroenteropancreatic neuroendocrine neo-plasm multidisciplinary team construction of regional centerof excellence
  • 相关文献

参考文献12

  • 1Yao JC, Hassan M, Phan A, et al. One hundred years after "car- cinoid": epidemiology of and prognostic factors for neuroendo- crine tumors in 35,825 cases in the United States[J].J Clin On-col, 2008,26(18) : 3063-3072.
  • 2Strosberg J, Gardner N, Kvols L.Survival and prognostic factor analysis of 146 metastatic neuroendoerine tumors of the mid-gut [ J ]. Neuroendocrinology,2009,89(4):471-476.
  • 3Susini C, Buscail L.Rationale for the use of somatostatin analogs as antitumor agents[Jl.Ann Oncol,2006,17(12): 1733-1742.
  • 4Searpa A, Mantovani W, Capelli P, et al.Pancreatic endocrine tu- mors: improved TNM staging and histopathological grading per- mit a clinically efficient prognostic stratification of patients [J]. Mod Pathol, 2010,23(6) : 824-833.
  • 5Modlin IM, Drozdov I, Kidd M.The identification of gut neuroen- docrine tumor disease by multiple synchronous transcript analy- sis in blood [ J ].PLoS One, 2013,8(5) : 63364.
  • 6Vicentini C, Fassan M, D'Angelo E, et al. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointesti- nal tract [ J ].Molecules, 2014,19(2): 2458-2468.
  • 7Kulke MH, Hornick JL, Frauenhoffer C, et ah O6-methylgua- nine DNA methyltransferase deficiency and response to temo- zolomide-based therapy in patients with neuroendocrine tumors[J].Clin Cancer Res,2009, 15(1): 338-345.
  • 8Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and roTOR pathway genes arm frequently altered in pancreatic neuroendo- crine tumors [J].Science, 2011,331 (6021) : 1199-1203.
  • 9Khan MS, Tsigani T, Rashid M, et ahCirculating tumor cells and EpCAM expression in neuroendoerine tumors [J].Clin Cancer Res,2011,17(2):337-345.
  • 10Faivre S, Ronot M, Dreyer C, et al. Imaging response in neuro- endocrine tumors treated with targeted therapies : the experi- ence of sunitinib[J].Target Oncol,2012,7(2): 127-133.

同被引文献27

  • 1Yao JC, Hassan M, Phan A, et al. One hundren years after carci- noid: epldemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 2008, 26 ( 18 ) :3063 - 3072.
  • 2Hamilton SR, Bosman PT, Boffeffa P, et al. Carcinoma of the colon and rectum. In: WHO Classification of tumors of the digestive sys- tem. Lyon: IARC press, 2010.
  • 3Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol, 2010,23 ( 6 ) : 824 - 33.
  • 42013年中国胃肠胰神经内分泌肿瘤病理诊断共识专家组.中国胃肠胰神经内分泌肿瘤病理诊断共识(2013版).中华病理杂志,2013,10(42):691-694.
  • 5Scoazec JY, Couvelard A, Monges G, et al. Well-differentiated grade 3 digestive neuroendoerine tumors: myth or realty? The PRONET study group. J Clin Oncol, 2012,30 (suppl) :4129.
  • 6Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resec- tions for small non-functioning pancreatic endocrine tumors. Ann Surg Oncol, 2010,17(6) :1621 - 1627.
  • 7Kuo E J, Salem RR. Population-level analysis of pancreatic neureen- docrine tumors 2cm or less in Size. Ann Surg Oncol, 2013, 20(9) : 2815 -2821.
  • 8Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrien tumors: the impact of surgical resection on survival. Cancer, 2009, 115(4) :741 -751.
  • 9Bettini R, Mantovani W, Boninsegna L, et al. Primary tumors resec- tion in metastatic nortfunctioning pancreatic endocrine carcinomas. Dig Liver Dis, 2009, 41 ( 1 ) :49 -55.
  • 10Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long- term survival in 118 consecutive patients with neuroendocfine tumours of the pancreas. Br J Surg. 2008, 95(5) :627 -35.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部